A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Inclusion Criteria:

- Histologically or cytologically confirmed solid tumors that are metastatic or
unrespectable for which carboplatin/gemcitabine is a treatment option.

- Eastern Cooperative Group performance score of 0 to 2.

- Adequate hematologic, hepatic and renal function

- Subject has received up to 2 DNA damaging or cytotoxic regimens in the past five
years

Exclusion Criteria:

- Subject has received any anti-cancer therapy including chemotherapy, immunotherapy,
radiotherapy, biologic or any investigational therapy within 28 days prior to study
administration.

- Subjects with known history of brain metastases and primary CNS tumors.

- Hypersensitivity reactions to platinum compounds or gemcitabine.

- Clinically significant and uncontrolled major medical conditions

- Active malignancy within the past 5 years except for any cancer in situ cured or
non-melanoma carcinoma of the skin.